Cart summary

You have no items in your shopping cart.

Flibanserin

SKU: orb1222623

Description

Flibanserin is a full agonist of the 5-HT1A receptor (Ki = 1 nM) and, with lower affinity, as an antagonist of the 5-HT2A receptor (Ki = 49 nM) and antagonist or very weak partial agonist of the D4 receptor (Ki = 4–24 nM). Despite the much greater affinity of flibanserin for the 5-HT1A receptor, and for reasons that are unknown, flibanserin occupies the 5-HT1A and 5-HT2A receptors in vivo with similar percentages. Flibanserin also has low affinity for the 5-HT2B receptor (Ki = 89.3 nM) and the 5-HT2C receptor (Ki = 88.3 nM), both of which it behaves as an antagonist of. Flibanserin preferentially activates 5-HT1A receptors in the prefrontal cortex, demonstrating regional selectivity, and has been found to increase dopamine and norepinephrine levels and decrease serotonin levels in the rat prefrontal cortex, actions that were determined to be mediated by activation of the 5-HT1A receptor.[12] As such, flibanserin has been described as a norepinephrine-dopamine disinhibitor (NDDI). Flibanserin was approved in August 2015 for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD).(In Vitro):Flibanserin (0.01-100 μM; 72 h) can transform into two degradation products DP1 and DP2 with no toxicity potential after oxidative degradation.(In Vivo):Flibanserin (1, 10, 30 mg/kg; i.p.; single dose) shows different pharmacological properties in prefrontal cortex, hippocampus and midbrain. The 5-HT1A receptor occupancy in cortex indicates it’s the more sensitive than other brain region.Flibanserin (15, 45 mg/kg; p.o.; twice a day; 22 d) preferentially activates the brain regions belonging to the mesolimbic dopaminergic pathway and hypothalamic structures involved in the integration of sexual cues related to sexual motivation.Flibanserin (5, 10, 25, and 50 mg/kg; s.c.; single dose) has anxiolytic effects without locomotor side effects in rat ultrasonic vocalization model.

Images & Validation

Key Properties

CAS Number167933-07-5
MW390.41
Purity>98% (HPLC)
FormulaC20H21F3N4O
SMILESFC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1
Target5-HT1A|5-HT2A
SolubilityDMSO : ≥ 45 mg/mL; 115.27 mM

Bioactivity

In Vivo
Flibanserin (1, 10, 30 mg/kg; i.p.; single dose) shows different pharmacological properties in prefrontal cortex, hippocampus and midbrain. The 5-HT1A receptor occupancy in cortex indicates it’s the more sensitive than other brain region. Flibanserin (15, 45 mg/kg; p.o. ; twice a day; 22 d) preferentially activates the brain regions belonging to the mesolimbic dopaminergic pathway and hypothalamic structures involved in the integration of sexual cues related to sexual motivation. Flibanserin (5, 10, 25, and 50 mg/kg; s. c. ; single dose) has anxiolytic effects without locomotor side effects in rat ultrasonic vocalization model. Animal model: Long Evans female rats (225-250 g). Dosage: 15 mg/kg; 45 mg/kg. Administration: Oral gavage; twice a day for 22 days. Result: Increased the density of activated catecholaminergic neurons in the ventral tegmental area but not in the locus coeruleus. Increased Fos expression in the medial preoptic area and arcuate nucleus of the hypothalamus, ventral tegmental area, locus coeruleus, and lateral paragigantocellular nucleus with chronic 22-day treatment. Animal model: Rat pup ultrasonic vocalization model of anxiety. Dosage: 5, 10, 25, and 50 mg/kg. Administration: Subcutaneous injection. Result: Reduced ultrasonic vocalizations in rat pups. Showed effective within 30 min and has no severe locomotor side effects at active doses.
In Vitro
Flibanserin (0.01-100 μM; 72 h) can transform into two degradation products DP1 and DP2 with no toxicity potential after oxidative degradation. Cell Viability Assay Cell line: NHSF cell lin. Concentration: 0.01, 0.1, 1, 10, 100 μM Incubation time: 72 hours. Result: Resulted cell viability reached to 97.91% (DP1) and 96.73% (DP2) at 0.01 μM.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

EBD6396 | Flibanserin. Brand name: Addyi

Similar Products

  • Flibanserin [orb1302975]

    99.93% (May vary between batches)

    167933-07-5

    390.4

    C20H21F3N4O

    5 mg, 50 mg, 100 mg, 10 mg, 25 mg, 1 ml x 10 mM (in DMSO), 200 mg
  • Flibanserin hydrochloride [orb1687718]

    147359-76-0

    426.87

    C20H22ClF3N4O

    25 mg, 100 mg, 50 mg
  • Flibanserin-d4 [orb1992855]

    2122830-90-2

    394.43

    C20H21F3N4O

    5 mg, 1 mg, 10 mg, 25 mg
  • Flibanserin-d4-1 [orb3138503]

    2122830-91-3

    394.43

    C20H21F3N4O

    10 mg, 50 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Flibanserin (orb1222623)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

5 mg
$ 80.00
10 mg
$ 110.00
25 mg
$ 170.00
50 mg
$ 280.00
100 mg
$ 430.00
500 mg
$ 990.00